期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 76, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2022.128988
关键词
Muscarinic acetylcholine receptor 5; mAChR; M5; Antagonist
资金
- Ancora Innovation, LLC
- William K. Warren Family and Foundation
- Vanderbilt Institute of Chemical Biology
- Vanderbilt Ingram Cancer Center [P30 CA68485]
The lack of suitable tool compounds has restricted the in vivo understanding of M5 receptor biology. In this article, the authors present their ongoing efforts to develop next-generation M5 antagonists with improved clearance profiles.
The lack of potent and selective tool compounds with pharmaceutically favorable properties limits the in vivo understanding of muscarinic acetylcholine receptor subtype 5 (M5) biology. Previously, we presented a highly potent and selective M5 antagonist VU6019650 with a suboptimal clearance profile as our second-generation tool compound. Herein, we disclose our ongoing efforts to generate next-generation M5 antagonists with improved clearance profiles. A mix and match approach between VU6019650 (lead) and VU0500325 (HTS hit) generated a piperidine amide-based novel M5 antagonist series. Several analogs within this series, including 29f, provided good on-target potency with improved clearance profiles, though room for improvement remains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据